HANGZHOU BIO-SINCEHH

HANGZHOU BIO-SINCE

50.70CNYD
+1.24+2.51%
At close at 08:49 GMT
CNY
No trades
See on Supercharts

301096 fundamentals

Key facts

Market capitalization‪5.40 B‬CNY
Basic EPS (TTM)−1.19CNY
Founded2011
Employees (FY)‪1.83 K‬
CEOJin Fang Lou
About

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. engages in the research and development of medicine and medical technology. It provide drug research and development services and transformation of research and development technology results for various pharmaceutical companies and pharmaceutical R&D investment companies. The company was founded on June 28, 2011 and is headquartered in Hangzhou, China.

Ownership
‪‪108.45 M‬‬
Free Float shares
‪‪83.94 M‬‬ (77.39%)
Closely held shares
‪‪24.52 M‬‬ (22.61%)
Free Float shares
‪‪83.94 M‬‬ (77.39%)
Closely held shares
‪‪24.52 M‬‬ (22.61%)
Capital structure
Market cap
‪‪5.40 B‬‬
Debt
‪‪851.59 M‬‬
Cash & equivalents
‪‪512.89 M‬‬
Enterprise value
‪‪5.74 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪5.40 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
7.61x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
7.61x
Valuation ratios
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪8.00‬
‪16.00‬
‪24.00‬
‪32.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−270%‬
‪−180%‬
‪−90%‬
‪0%‬
‪90%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−320.00 M‬‬
‪‪−160.00 M‬‬
‪0.00‬
‪‪160.00 M‬‬
‪‪320.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−45.00 M‬‬
‪0.00‬
‪‪45.00 M‬‬
‪‪90.00 M‬‬
‪‪135.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−45.00 M‬‬
‪0.00‬
‪‪45.00 M‬‬
‪‪90.00 M‬‬
‪‪135.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Transformation of Independent Research and Development Technological Achievements
Clinical Services
Preclinical Pharmaceutical Research
Customized Research and Development and Production
Commercial Production
Other
Equity Share
By country
Period: 2024
China

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
‪‪320.00 M‬‬
Actual
Earnings
Next:Apr 29, 2026
2021
2022
2023
2024
2025
‪−0.90‬
‪0.00‬
‪0.90‬
‪1.80‬
‪2.70‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.61%
Last payment
0.30
Last ex-date
Jun 3, 2024
Last pay date
Jun 3, 2024
Dividend history
‪0.0%‬
‪0.3%‬
‪0.6%‬
‪0.9%‬
‪1.2%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.20‬
‪0.40‬
‪0.60‬
‪0.80‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−400.00 M‬‬
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
‪‪2.40 B‬‬
Assets
Liabilities